 Connection
Mary Weiser-Evans to Polycystic Kidney Diseases
This is a "connection" page, showing publications Mary Weiser-Evans has written about Polycystic Kidney Diseases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.398 |
|
|
|
-
Miller SJ, Zhong H, Wu W, Cordova AM, Yashchenko ME, Yashchenko A, Li Z, Jafree DJ, Zimmerman CN, DeVette CI, Do V, Hignite ME, Park Y, Nusrat F, Maryam B, Lu S, Li X, Gipson JR, Li X, Long DA, Weiser-Evans MC, Yoder BK, Cowley BD, Hopp K, Stubbs JR, Ma Q, Ma A, Zimmerman KA. A cross-model single-cell atlas reveals conserved involvement of osteopontin in polycystic kidney disease. JCI Insight. 2026 Sep 08; 11(17).
Score: 0.224
-
Holditch SJ, Brown CN, Atwood DJ, Pokhrel D, Brown SE, Lombardi AM, Nguyen KN, Hill RC, Lanaspa M, Hopp K, Weiser-Evans MCM, Edelstein CL. The consequences of increased 4E-BP1 in polycystic kidney disease. Hum Mol Genet. 2019 12 15; 28(24):4132-4147.
Score: 0.141
-
Montford JR, Bauer C, Dobrinskikh E, Hopp K, Levi M, Weiser-Evans M, Nemenoff R, Furgeson SB. Inhibition of 5-lipoxygenase decreases renal fibrosis and progression of chronic kidney disease. Am J Physiol Renal Physiol. 2019 04 01; 316(4):F732-F742.
Score: 0.033
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|